** Shares of gene therapy developer Lexeo Therapeutics
rise 13.62% to $8.74 premarket
** Co says reached alignment with FDA on registrational development plan for LX2006 to support an accelerated approval pathway
** LX2006 is being developed as a gene therapy that is delivered intravenously for the treatment of Friedreich's ataxia cardiomyopathy
** Friedreich's ataxia is a genetic multi-system disorder and 80% of patients are estimated to develop cardiomyopathy, a type of heart disease
** LX2006 was granted regenerative medicine advanced therapy (RMAT) designation to accelerate development - LXEO
** Brokerage Stifel says alignment is a big win
** Up to last close, stock down ~42% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。